Amplify Weight Loss Drug ... (THNR)
El precio, las cifras principales y las últimas noticias, en un solo sitio.
Amplify Weight Loss Drug & Treatment ETF (THNR): cotización, análisis y datos
No hay datos disponibles
| Precio de compra | 27.5 |
| Capitalización de mercado | n/a |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | n/a |
| n/a | |
| n/a | |
| 19.95 | |
| n/a | |
| P/B (TTM) | n/a |
| P/S (TTM) | n/a |
| Fecha de resultados | n/a |
| Precio de venta | n/a |
| Volumen | 9,624 |
| Volumen medio (20D) | 2,193 |
| Abierto | 27.80 |
| Anterior Cerrar | 27.54 |
| Rango del día | 27.41 - 27.55 |
| Rango de 52 semanas | 22.63 - 27.80 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de THNR
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, includ...
Desempeño financiero
En undefined, los ingresos de Amplify Weight Loss Drug & Treatment ETF fueron n/a, un aumento de undefined% en comparación con n/a del año anterior. Las ganancias fueron n/a, un aumento de undefined%.
Estados financieros
